# CUREMETRIX COMPLETES FUNDING TO ACCELERATE ADOPTION OF AI SOFTWARE IN MEDICAL IMAGING

CureMetrix Closes Investment by the Managing Partners of Bold Brain Ventures To Bridge The Gap Between Radiologists and Cutting-Edge AI Software

SAN DIEGO, CA, UNITED STATES, November 26, 2018 / EINPresswire.com/ -- CureMetrix, a San Diego-based company developing a deep learning algorithm that allows radiologists to get more specific readings on breast images, announces an investment by the Managing Partners of Bold Brain Ventures, the first and only investment fund to focus on radiology artificial intelligence (AI) with radiologists as the key investors, advisors and managers. This investment was a personal investment made by the partners of Bold Brain Ventures, and will be warehoused into the fund when the fund goes live after its first close.

> **"**
>
> We made a personal investment in CureMetrix because we believe that the field of breast imaging needs the assistance that AI can provide to improve patient care."
>
> *Robin Prasad, MD, MS, MBA, Managing Partner, Bold Brain Ventures*

CureMetrix plans to use the funding to accelerate the commercialization of its AI-based computer-aided detection software (AI-CAD), cmAssist, it's workflow optimization solution, cmTriage, and several other products intended to increase the efficacy of medical image analysis.

"Our involvement in CureMetrix represents far more than just capital. We made a personal investment in CureMetrix because we believe that the field of breast imaging needs the assistance that AI can provide to improve patient care. When the fund goes live, we hope to be able to offer the collective expertise of a group of radiologists who can help drive forward the company's innovation, provide access to new distribution channels and data and forge an effective partnership between AI and doctors," says Robin Prasad, MD, MS, MBA, managing partner of Bold Brain Ventures.

Kevin Harris, CEO of CureMetrix, commented: "Our goal is to help radiologists recognize the value of combining the artificial intelligence of the software with the real intelligence of radiologist to optimize their workflow, improve efficiency and accuracy, reduce costs and improve patient outcomes. Our software solutions are primed for continued global exposure and adoption – we have a CAD that works. This strategic investment will help CureMetrix AI solutions become more trusted by radiologists and more prolific in healthcare institutions

throughout the world, ultimately, saving more lives." CureMetrix is honored to have the Managing Partners of Bold Brain Ventures as investors in this round, in addition to founding investors Analytics Ventures, XB Ventures & Innova Salud. This hands-on team of investors has helped propel CureMetrix to a global stage.

CureMetrix has collected over one million images to date, from leading institutions across the United States and around the world, to train and validate its proprietary algorithm so it can recognize and quantify regions of interest on a mammogram. Independent testing by leading institutions has demonstrated the CureMetrix algorithm has best-in-class efficacy and is becoming the leader in AI-CAD for the breast. The company is currently working towards FDA approval for its software solutions.

For more information on CureMetrix or potential investment opportunities please contact info@curemetrix.com.

About CureMetrix
CureMetrix® was founded in 2014 on the belief that better medical image analysis technology could lead to better outcomes for breast cancer patients. The company is developing investigational physics-based artificial intelligence and deep machine learning solutions to help radiologists get more accurate readings of breast images. Through its research partnerships with leading hospital radiology departments, CureMetrix has evaluated more than 500,000 mammogram images to identify potential false negatives, which are undiagnosed cancers, and false positives, which are unnecessary recalls of patients to review anomalies that turn out to be normal. False negatives can occur at a rate of about one in five breast cancers.1 False positives affect 7-12 percent of all women after an initial mammogram.2 Reducing false positives could save a significant portion of the $4 billion per year spent on unneeded and sometimes invasive procedures such as biopsies.3 More importantly, reducing false negatives could save lives as well as reduce the cost and difficulty of cancer treatment through early detection.

Our goal is to create CAD that Works®. Improving computer-aided diagnosis (CAD) through a more robust physics-based algorithm for detecting and diagnosing breast and all cancers empowers radiologists, supports their patients and reduces costs while improving clinical outcomes. To learn more about CureMetrix, visit www.curemetrix.com.

1 https://www.cancer.org/cancer/breast-cancer/screening-tests-and-early-detection/mammograms/limitations-of-mammograms.html
2 http://ww5.komen.org/BreastCancer/AccuracyofMammograms.html
3 http://content.healthaffairs.org/content/34/4/576.abstract

Elise Crispen
CureMetrix
+1 858-345-6061
email us here

This press release can be viewed online at: http://www.einpresswire.com